Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBTXR3 with radiotherapy and anti-PD-1 in advanced cancers
NCT03589339Phase 1Active, not recruiting
- Sponsor
- Nanobiotix
- Start
- Jan 2019
- Primary completion
- Apr 2027
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NBTXR3 in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), Malignant Melanoma (MM) and 5 more, sponsored by Nanobiotix. Primary endpoints: Recommended Phase 2 Dose at 24 months and Safety Evaluation at Recommended Phase 2 Dose at 24 months. Started Jan 2019; status: active, not recruiting.
02
Drugs
NBTXR3
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)Malignant Melanoma (MM)hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03589339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03589339.